Hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors: ready for primetime?. Issue 5 (15th September 2022)

• Record Type: Journal Article
• Authors: Macdougall, Iain C.
• Is Part Of: Current opinion in nephrology and hypertension. Volume 31:Issue 5(2022)
• Page Start: 399
• Page End: 405
• Publication Date: 2022-09-15
• Subjects: anemia -- chronic kidney disease -- erythropoiesis -- hypoxia-inducible factor prolyl hydroxylase inhibitors -- hypoxia inducible factor; Hypertension -- Periodicals; Nephrology -- Periodicals; Hypertension -- Indexes; Hypertension -- Periodicals; Kidney Diseases -- Indexes; Kidney Diseases -- Periodicals; Nephrology -- Periodicals; 616.132
• DOI: 10.1097/MNH.0000000000000813
• Languages: English
• ISSNs: 1062-4821

Abstract

Abstract : Purpose of review: Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors have recently been developed as a new treatment for anemia associated with chronic kidney disease (CKD). Several of these have been approved in Europe (roxadustat), China, and Japan, but none approved in the United States to date, although daprodustat has been submitted as a new drug application to the Food and Drug Administration. The aim of this review is to critically appraise the available data, particularly the most recent publications, and offer a personal viewpoint on whether or not these drugs are ready for primetime. Recent findings: The efficacy of HIF prolyl hydroxylase inhibitors in improving CKD anemia and maintaining a higher hemoglobin is undisputed, but there remain some concerns about safety, particularly in the long term. Some of the safety concerns may result from an exaggerated pharmacological response, while other potential adverse effects could be due to transcriptional effects of these agents beyond genes involved in erythropoiesis. Summary: HIF prolyl hydroxylase inhibitors are already being used in clinical practice in several countries of the world, and ongoing research is being conducted to define the role of these drugs not only in the management of anemia but also beyond into other clinical settings.